NantHealth (NH) Lowered to Sell at Zacks Investment Research

NantHealth (NASDAQ:NH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “

A number of other equities research analysts have also issued reports on the stock. BidaskClub lowered shares of NantHealth from a “buy” rating to a “hold” rating in a report on Friday, June 22nd. ValuEngine raised shares of NantHealth from a “hold” rating to a “buy” rating in a report on Monday, July 2nd. Finally, Canaccord Genuity reissued a “hold” rating on shares of NantHealth in a report on Tuesday, July 3rd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. NantHealth has a consensus rating of “Hold” and a consensus price target of $4.31.

NantHealth stock opened at $1.41 on Tuesday. NantHealth has a 52-week low of $1.30 and a 52-week high of $4.53. The firm has a market cap of $171.87 million, a PE ratio of -1.26 and a beta of -0.01. The company has a quick ratio of 1.48, a current ratio of 1.50 and a debt-to-equity ratio of 1.34.

NantHealth (NASDAQ:NH) last released its earnings results on Thursday, August 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.01. NantHealth had a negative net margin of 124.02% and a negative return on equity of 49.56%. The business had revenue of $22.05 million during the quarter, compared to analyst estimates of $24.50 million. Equities research analysts anticipate that NantHealth will post -0.63 EPS for the current fiscal year.

An institutional investor recently raised its position in NantHealth stock. Dimensional Fund Advisors LP lifted its position in NantHealth Inc (NASDAQ:NH) by 41.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 120,348 shares of the company’s stock after purchasing an additional 35,445 shares during the quarter. Dimensional Fund Advisors LP owned about 0.11% of NantHealth worth $398,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 5.63% of the company’s stock.

NantHealth Company Profile

NantHealth, Inc, together with its subsidiaries, operates as an evidence-based personalized healthcare company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care.

Further Reading: Understanding Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on NantHealth (NH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply